Author Archive | Raynovich Rod

NASDAQ Rolls On To 10 Year High At 3016 Up 1%

Biotech Sector (IBB $119.73)  Up 12 % YTD, Lagging NASDAQ (QQQ) Up 17.85% Here is a summary of our recommendations over  the past month: No change in our basic Rayno Life Science Portfolios.Biopharmaceuticals have outperformed Tools and Diagnostics. Continued strength with following stocks at or near new highs are : Amgen (AMGN $68.43), Biogen (BIIB […]

Continue Reading 0

Snow Blog West: Snowy Period by March 17th

All the Models Looking Better for PPT We should see a change by next weekend for one of the worst Sierra seasons in recent times. Mammoth has a good base due to excellent man made snow, but has received only 157 in. of snow season TD compared to an average of 342 in., and the […]

Continue Reading 0

Biotech Stocks Ignited on JNJ Prostate Drug Study

Biotech Sector Recovers from Monday’s Weakness-Bull Intact Biotech stocks are strong today tracking a NASDAQ rally and favorable news on JNJ’s prostate drug Zytiga which met its goal in a new study. Dendreon stock took a big hit down 10% because the JNJ therapy is simpler and cheaper, while Medivation (MDVN $74) stock soared 14% […]

Continue Reading 0

Illumina (ILMN $50.35) Good Value

CEO Jay Flatley was on CNBC at 4:55p today with Maria Bartiromo. Maria asked him why the Company did  not accept the Roche offer? He answered ” because the offer was near  the stock’s low for the year and was opportunistic and did not reflect the  value of the Company.” Flatley also reiterated the huge […]

Continue Reading 0

Sell-Off Picks Up With Some Biotechs Hit Hard

Smaller Cap Biotechs  In Major Correction All the major indices are down in the 1.75% range and now the NASDAQ at 2902 is 100 pts. away from the elusive 3000 level. Analysts have been warning about a correction for weeks but with many indices up 10-15% YTD profit taking was inevitable. Driving prices lower were […]

Continue Reading 0

Caution Rules: Easy Money Has Been Made With Biotech Up 15% YTD

Pause Mode Since February 15 The biotech indices and ETF’s we track are off about 1% or more today as the market is in a profit taking mode. The Rayno Life Science Portfoio is also off about 1%. Speculative appetite is down with some MO stocks and former high-fliers taking a greater hit today: Amarin […]

Continue Reading 0

Biotech Bull Market Intact But Due For A Pause

Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over the past five days driven by  News from Vivus (VVUS) and Threshold (THLD) the IBB ($119.78) is still off its one year […]

Continue Reading 0

Another Daily Reversal : Take More Off in Biotech

Have you read the book “Think Fast,Think Slow” by Daniel Kahneman? Well my System 1 (fast, intuitive and emotional) brain sees a lot of red on the screen telling me to take profits. If you want System 2 (slower, more deliberative, more logical) data to support this I can only offer the following without extensive […]

Continue Reading 0

Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen

$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of Q1 and Q2. Some analysts saw the stock drop as buying opportunity-11 […]

Continue Reading 0

No Panic Just Take A Little Off:Caution- Update Rally 2/16

Market Reversal and a  Light Sell-Off Technicals and a market reversal particularly a $20+ drop in AAPL gives us reason to take profits or hedge after a great start to 2012. The S&P is up  7% YTD,  NAZ up 12% YTD, and the IBB biotech ETF up 16% YTD near its all time high. Some […]

Continue Reading 0